T-STEMNCT07825857
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Oct 1, 2026 to Oct 23, 2026
- Site details revised at 4 of 4 sites
- Minor Study sites: 3 to 4
- Minor Study description expanded, about 9 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Treatment response
Timeframe: 26 weeks
Secondary (6)
Tolerability - stopping of treatment
Current craving for methamphetamine
Early remission
Safety - occurrence of serious adverse event
Reduction in self-reported use of methamphetamine
Show 1 moreShow less
Worst past-week craving for methamphetamine
Arms and interventions
TirzepatideExperimental
Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 26-week period.
Placebo (Saline)Placebo comparator
Eligible participants who are enrolled will receive once-weekly subcutaneous injections of saline for a 26-week period.
Drugs: Tirzepatide, Placebo (saline)
Sites
4 sites in 1 country